Table 2 Glycemic outcomes, lipids and liver enzymes in patients with IGT, at baseline and after 12 weeks’ treatment or placebo

Fasting-glucose (mmol/l)

6.7 ± 0.4

6.0 ± 0.3

0.370

6.1 ± 0.4

0.205

6.1 ± 0.4

0.735

Fasting-insulin (mlE/l)

11.1 ± 2.0

9.8 ± 2.1

0.481

8.5 ± 1.6

0.034*

9.0 ± 2.5

0.284

HbA1c (mmol/mol)

40.1 ± 2.4

39.6 ± 1.3

0.815

40.1 ± 1.8

0.786

40.2 ± 1.6

0.320

Cholesterol (mmol/l)

4.5 ± 0.2

4.9 ± 0.4

0.673

4.4 ± 0.2

0.670

4.6 ± 0.3

0.482

LDL Cholesterol (mmol/l)

2.7 ± 0.2

3.2 ± 0.4

0.606

2.6 ± 0.3

0.528

2.9 ± 0.2

0.553

HDL Cholesterol (mmol/l)

1.5 ± 0.1

1.4 ± 0.1

0.888

1.5 ± 0.1

0.774

1.4 ± 0.1

0.414

Triglycerides (mmol/l)

1.1 ± 0.1

1.1 ± 0.1

0.888

1.0 ± 0.2

0.686

1.0 ± 0.1

0.101

ASAT (μkat/l)

0.38 ± 0.04

0.40 ± 0.05

0.888

0.38 ± 0.04

0.752

0.41 ± 0.05

0.445

ALAT (μkat/l)

0.39 ± 0.07

0.50 ± 0.09

0.481

0.38 ± 0.08

0.528

0.49 ± 0.09

0.799

ALP (μkat/l)

0.89 ± 0.05

1.04 ± 0.13

0.541

0.86 ± 0.06

0.161

1.10 ± 1.28

0.128

GT (μkat/l)

0.37 ± 0.07

0.58 ± 0.15

0.370

0.36 ± 0.06

0.674

0.71 ± 0.25

0.313

Bilirubin (μmol/l)

9.2 ± 1.1

9.9 ± 1.6

0.963

8.5 ± 1.1

0.197

11.6 ± 2.0

0.087

Pk (INR)

1.04 ± 0.02

1.0 ± 0.02

0.888

1.01 ± 0.02

0.157

1.0 ± 0.02

0.317